Sold and Supplied by Healthylife Pharmacy
This product is a Prescription Only Medicine (S4) and is sold by Healthylife Pharmacy, an independently owned and operated pharmacy business. This prescription product requires a valid Australian script.
Medicare CardNo MedicareConcession
$26.95
Healthylife provides general product information such as nutritional information, country of origin and product packaging for your convenience. This information is intended as a guide only, including because products change from time to time. Please read product labels before consuming. For therapeutic goods, always read the label and follow the directions for use on pack. If you require specific information to assist with your purchasing decision, we recommend that you contact the manufacturer via the contact details on the packaging or email us at [email protected]. Product ratings and reviews are taken from various sources including Bazaarvoice. Healthylife does not represent or warrant the accuracy of any statements, claims or opinions made in product ratings and reviews.
Keep reading to learn about this prescription only medication and its important details. Always consult your healthcare provider before taking any medication including this prescription only medication or any other product. This medication is available only for you. Do not stop taking this medication without asking your doctor or pharmacist. Healthylife does not create FSA listings and does not imply any specific product or condition (such as product description) or disease or allergyeltistance (e.g. based on your income) as the absence ofHAFT-DRDDR-like content may cause harm. Allergic reactions to this product require immediate medical attention. If you are allergic to metformin, you should not use. Do not discontinue this medication without consulting your doctor.Healthylife.auHealthylife.au provides a safe and effective therapeutic option for individuals with diabetes, high blood pressure, high cholesterol, or other conditions that cause fluid retention or high blood pressure. Please consult your doctor for personalized advice about using this product. Please read the enclosed leaflet for more information about this medicine. Healthylife.au does not represent or warrant the accuracy of the medical information provided.
Product information available| Metformin (500mg) |
| Other brand names (e.g. Glucophage) |
Treatment of type 2 diabetes mellitus (non-insulin-dependent diabetes), particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycemic control: in adults, metformin (Glucophage) may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin; in children from 10 years of age and adolescents, metformin (Glucophage) may be used as monotherapy or in combination with insulin. Intensive glucose control with metformin as first-line therapy in overweight type 2 diabetes mellitus (non-insulin-dependent patients) has been shown to reduce diabetes complications. Prevention of type 2 diabetes mellitus in adults.
Glucophage/Glucophage Forte:Unless otherwise prescribed, the dosage and administration is as follows:Adults:Monotherapy or in combination with other oral antidiabetic agents:The usual starting dose is one tablet of metformin (Glucophage) 500 mg or one tablet of metformin (Glucophage Forte) 850 mg, 2 or 3 times daily given during or after meals. Metformin (Glucophage) must be taken daily without interruption, except if specifically indicated by the doctor. Metformin (Glucophage) must be taken at the same time each day. Metformin (Glucophage) can be taken with or without food. The metformin (Glucophage) tablets and metformin (Glucophage Forte) can be taken with or without food. The tablets should be translucent colorless. The amount of metformin in the tablet is no greater with a day after the metformin (Glucophage) starting day than before the metformin (Glucophage) starting day. There should be no specific limit to the number of tablets of metformin (Glucophage) that may be taken in the following three or more his or your the doctorx: monotherapy or in combination with other oral antidiabetic agents, in which case the dosage and duration of treatment necessary to maintain control can be given without further medication. (i.e. treatment in the morning and evening must be limited to 30 minutes after the beginning of the treatment day; treatment in the evening and night must be limited to 30 minutes after the beginning of the treatment day; with or without water, time limit can be extended to one hour per treatment day. With or without food, treatment with metformin (Glucophage) does not increase the time to weight gain of treated weight gain and cannot be used without clarifying the diet.) with or without water, if alcohol and metformin not meets treatment with metformin (Glucophage) will be used to prevent blood clots and may be used without additional medication as soon as subsequent therapy is started without further medication. With or without alcohol can also be used to improve glycemic control in patients with type 2 diabetes who have experienced weight gain and loss due to raised blood pressure, and in patients who have experienced these symptoms after metformin (Glucophage) starting with additional medication are vomiting, loss of appetite and other blood pressure changes and increased heart rate. If metformin (Glucophage) starting with additional medication starts without further medication then the blood pressure and diastolic blood pressure can be measured 2 h, and 15 days, after the metformin (Glucophage) finishing the course of treatment. Treatment with metformin (Glucophage) starting with metformin (Glucophage) should be maintained for at least of at least 24 weeks, therefore no additional duration of treatment is required after 12 weeks of treatment with metformin (Glucophage). For the treatment of type 2 diabetes mellitus, metformin (Glucophage) should be used first- or second-line or as a combination with insulin as initial treatment or with metformin (Glucophage) at the same time as metformin (Glucophage) starting with metformin (Glucophage) whether or mean or long-acting oral insulin is first- or second-line.
Objectives:The primary objective of this study was to evaluate the efficacy of metformin HCl oral extended-release tablets as monotherapy or combination therapy with insulin glargine HCl oral extended-release tablets in reducing insulin resistance. The secondary objective was to compare the safety of metformin HCl oral extended-release tablets and insulin glargine HCl oral extended-release tablets.
Methods:In this single-center, double-blind, placebo-controlled, randomized, single-dose trial, 16 obese subjects with body mass index (BMI) of 25 to 35 kg/m2 were recruited for the study. Exclusion criteria were: patients with known malignancy, liver or kidney dysfunction, and concomitant use of any other diabetes medication. Subjects were treated with either metformin HCl oral extended-release tablets or insulin glargine HCl oral extended-release tablets. All subjects underwent biochemical measurements, and fasting glucose, triglycerides, and C-reactive protein were measured before metformin HCl oral extended-release tablets and during metformin HCl oral extended-release tablets. Baseline and follow-up clinical data were collected. After metformin HCl oral extended-release tablets was administered, fasting glucose, total and LDL-C and total cholesterol levels were measured. Blood samples for glucose and triglyceride levels were obtained before and after metformin HCl oral extended-release tablets. All subjects were monitored for adverse events, and glucose concentrations were measured. A fasting blood sample was taken before metformin HCl oral extended-release tablets and for each subject, and the fasting triglycerides and cholesterol levels were measured. Blood samples for glucose and triglyceride levels were taken at baseline and during metformin HCl oral extended-release tablets. All subjects were monitored for adverse events and LDL-C levels were measured. Data analysis was performed using SPSS version 23.0. The significance level for the primary endpoint was P<0.05.
Results:The study was terminated early because of adverse events and drug-related complications. The patients were treated with metformin HCl oral extended-release tablets and insulin glargine HCl oral extended-release tablets. The mean age was 57.6 years (SD±11.3) with a range of 22 to 85 years. The mean BMI was 28.1 kg/m2 (range 21.5 to 40 kg/m2) and 27.7 kg/m2 (range 21.4 to 41.6 kg/m2) with a range of 22 to 46 kg/m2 (range 22.8 to 39 kg/m2). The mean LDL-C was 48.2 mmol/L (range 17.2 to 113.8) and LDL-C level was 22.8 mmol/L (range 8.6 to 51.9). The mean fasting glucose, triglycerides and C-reactive protein levels were 6.2 (2.6 to 7.3), 9.8 (3.6 to 11.4), and 3.5 (2.1 to 6.5) mmol/L, respectively. The mean fasting C-reactive protein levels were 2.8 (2.4 to 3.4) and 2.1 (1.6 to 3.3) mmol/L. There was no statistically significant difference in the mean fasting blood pressure levels between the metformin and placebo groups (P>0.05).
Conclusion:This study demonstrated that metformin HCl oral extended-release tablets is effective and safe in reducing insulin resistance.
A study involving 16 obese subjects:A single-center, double-blind, placebo-controlled, randomised, crossover study was conducted to compare the efficacy and safety of metformin HCl oral extended-release tablets versus insulin glargine HCl oral extended-release tablets in decreasing insulin resistance. The primary efficacy measure was the decrease in insulin resistance. The secondary efficacy measures were the changes in insulin resistance, blood glucose, total cholesterol, HDL-C, LDL-C, triglycerides, total protein, and apolipoprotein B levels. A single-center, double-blind, placebo-controlled, crossover study was conducted to compare the efficacy and safety of metformin HCl oral extended-release tablets versus insulin glargine HCl oral extended-release tablets in reducing insulin resistance.
Citation:Jin L, Wang ZL, Wang Y, Zhang Y, Wu Q, et al.
Generic Name:Metformin Hydrochloride
Drug Class:Glucophage Oral Solution
Purpose:Insulin analogs, metformin diuretics, metformin hydrochloride
Uses:For managing type 2 diabetes mellitus, including type 2 diabetes. For managing type 1 diabetes mellitus, including type 1 diabetes mellitus, metformin hydrochloride is used to treat diabetic nephropathy in the kidneys, a condition in which the blood sugar level stays high for too long leading to reduced kidney function. Metformin HCl is used to treat diabetes mellitus. Metformin HCl can also be used for the management of diabetes-related swelling and/or pain in the lower extremities. If you are considering taking metformin hydrochloride as an oral solution, please consult your doctor before using this product.
Dosage:For the management of type 1 diabetes mellitus, including type 1 diabetes mellitus, metformin hydrochloride is usually used once daily. Your doctor will decide the dosage based on your condition and the degree of glycemic control you need. Always follow your doctor’s instructions carefully. For children weighing less than 30 pounds, please consult your doctor.
Administration:For the management of type 2 diabetes mellitus, including type 2 diabetes mellitus, metformin hydrochloride is usually given orally with meals.
Storage:Store this medication at room temperature, away from heat and moisture.
Ingredients:Each tablet contains Metformin Hydrochloride.
Take metformin tablets exactly as instructed by your doctor. Swallow the tablets whole with a full glass of water. Follow your doctor’s instructions carefully. You may take metformin tablets with or without food. If you miss a dose, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take a double dose to make up for a missed one.
Follow the directions on your prescription label. Take metformin exactly as directed.
Follow your doctor’s dosing schedule. Do not crush, chew, or break the tablets. The tablets should be used at the same time each day. Follow your doctor’s dosing schedule as directed.
You may take metformin with or without food.
Store the tablets at room temperature, away from heat and moisture. Keep out of the reach of children.
Do not use Metformin HCl if it is not being given correctly. Inform your doctor if you are pregnant, planning to become pregnant, or if you have any other medical conditions. Your doctor will determine the dosage and length of treatment if you are pregnant or breastfeeding.
Take your next dose at the normal time.
Stade de France Pharmacy